Last reviewed · How we verify

NCT06313151

The 2019 EULAR/ACR Classification Criteria as Predictor of Organ Damage in Systemic Lupus Erythematosus Patients

Status unknown Last updated 15 March 2024
What this trial tests

trial in SLE, and Organ Damage Index in 200 participants. Status unknown.

Timeline
10 March 2024
Primary endpoint
15 January 2026
15 March 2026

Quick facts

Lead sponsorSohag University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment200
Start date10 March 2024
Primary completion15 January 2026
Estimated completion15 March 2026
Sites1 location across Egypt

Conditions studied

Sponsor

Sohag University

Who can join

Adults 16 to 60, any sex, with SLE, and Organ Damage Index. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to investigate if the 2019 EULAR/ACR classification criteria can be used to assess organ damage in patients with systemic lupus erythematosus (SLE) and as predictor for prognosis .

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06313151.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing